{"id":830497,"date":"2025-03-27T08:09:54","date_gmt":"2025-03-27T12:09:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/"},"modified":"2025-03-27T08:09:54","modified_gmt":"2025-03-27T12:09:54","slug":"new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/","title":{"rendered":"New Data to Be Presented at Upcoming Congresses Showcase Cerevance&#8217;s Advanced Clinical Program in Parkinson\u2019s Disease and Deep Pipeline for CNS-based Disorders"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">Topline results from Phase 2 ASCEND trial of solengepras as a monotherapy treatment for early-stage Parkinson\u2019s to be presented<\/li>\n<li>First presentation of data from Phase 1 trial of novel KCNK13 inhibitor for CNS diseases targeting neuroinflammation<\/li>\n<li>Additional meeting presentations highlight potential of proprietary NETSseq platform to identify novel therapeutic targets for neurodegenerative diseases<\/li>\n<\/ul>\n<p>\u200dBOSTON, March  27, 2025  (GLOBE NEWSWIRE) &#8212; Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders, today announced upcoming presentations at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (AD\/PD\u2122 2025) being held April 1-5 in Vienna, and the American Academy of Neurology (AAN) Annual Meeting being held April 5-9 in San Diego.<\/p>\n<p>\n        <strong>Details of the oral presentation at <\/strong><br \/>\n        <strong>AD\/PD\u2122 2025 <\/strong><br \/>\n        <strong>are as follows:<\/strong>\n      <\/p>\n<p>\n        <strong>Title<\/strong>: Results of ASCEND: A Phase 2 Trial of Solengepras (CVN424) as an Investigational Monotherapy for Treatment of Early Parkinson\u2019s Disease<\/p>\n<ul type=\"disc\">\n<li>Presenter: Aaron L. Ellenbogen, DO, MPH<\/li>\n<li>Session Date\/Time: Tuesday, April 1, 2025, 1:15 p.m. CEST \/ 4:15 a.m. PT<\/li>\n<\/ul>\n<p>\n        <strong>Details of the poster presentations at the AAN 2025 Annual Meeting are as follows: <\/strong>\n      <\/p>\n<p>\n        <strong>Title:<\/strong> NETSseq Identifies Novel Therapeutic Targets for Neurodegenerative Diseases (#3592)<\/p>\n<ul type=\"disc\">\n<li>Presenter: Sagar Vaidya, M.D., Ph.D.<\/li>\n<li>Session Date\/Time: Sunday, April 6, 2025, 11:45 a.m. PT<\/li>\n<\/ul>\n<p>\n        <strong>Title:<\/strong> A First-in-Human Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation (#3282)<\/p>\n<ul type=\"disc\">\n<li>Presenter: Sagar Vaidya, M.D., Ph.D.<\/li>\n<li>Session Date\/Time: Tuesday, April 8, 2025, 8 a.m. PT<\/li>\n<\/ul>\n<p>\n        <strong>Title:<\/strong> Solengepras (CVN424): A Novel GPR6 Inhibitor in Clinical Development as an Investigational Therapy for Parkinson\u2019s Disease (#2892)<\/p>\n<ul type=\"disc\">\n<li>Presenter: Kelvin L. Chou, M.D., FAAN<\/li>\n<li>Session Date\/Time: Wednesday, April 9, 2025, 8 a.m. PT<\/li>\n<\/ul>\n<p>\n        <strong>About Cerevance<\/strong><br \/>\n        \n      <\/p>\n<p>Cerevance is focused on advancing cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders. Our proprietary platform, <strong>N<\/strong>uclear <strong>E<\/strong>nriched <strong>T<\/strong>ranscript <strong>S<\/strong>ort <strong>seq<\/strong>uencing (NETSseq), allows us to identify targets that are expressed at very low levels, that are present in rare cell types, or that change over time as a disease progresses. Our most advanced investigational treatment, solengepras, is currently in Phase 3 development and has the potential to be a first-in-class, oral non-dopaminergic therapy for both motor and non-motor symptoms of Parkinson&#8217;s disease. Our second investigational therapy, CVN766, is designed to be a highly selective oral antagonist of the orexin 1 receptor for the potential treatment of binge eating disorder and schizophrenia. Our third investigational treatment, CVN293, is a highly selective investigational oral inhibitor targeting potassium two pore domain channel subfamily K member 13 (KCNK13). CVN293 represents a potentially novel intervention point for neurodegenerative disorders and obesity. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oq1mfjeL5JxGosJExCTLII3MOXfGRdPyEt4hctzCaMHGvTx9Kw1rVH7fK0e3pqcagHlbtmpKpyEoB7k4ObpSIZuUY8hw6A_Yft7u4zjmFnU=\" rel=\"nofollow\" target=\"_blank\">www.cerevance.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8mOWMaw0NO6fG4mVJbiI-7YP0JkEA-TjLxGKsmF_WP11IX7uY4u1Z8WSpA3eEcHubdB1tRvS9oGVtMm9zNYPd7ry-3Wjz1d0_daHwLRM3vY=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hwl4kBHiv6AhH7zRXpynjH_uIZe8gejTSXTjxncLgWynetclgWZAWDIMZknzWQytvIYjjHDzAnCvzwe33M2HDA==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Contacts\u00a0<\/strong><br \/>\n        <br \/>\n        <strong>Cerevance:\u00a0<\/strong><br \/>\n        <br \/>Johnna Simoes, ir@cerevance.com<\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>April Dovorany, adovorany@realchemistry.com, +1-262-909-8739<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTI1OCM2ODMzOTA5IzIyOTg1NTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjRkMzZiNDEtYzI3MS00N2JlLTkxYWMtMTBlNTg4MmQ1MzU5LTEzMTAxMDctMjAyNS0wMy0yNy1lbg==\/tiny\/Cerevance-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Topline results from Phase 2 ASCEND trial of solengepras as a monotherapy treatment for early-stage Parkinson\u2019s to be presented First presentation of data from Phase 1 trial of novel KCNK13 inhibitor for CNS diseases targeting neuroinflammation Additional meeting presentations highlight potential of proprietary NETSseq platform to identify novel therapeutic targets for neurodegenerative diseases \u200dBOSTON, March 27, 2025 (GLOBE NEWSWIRE) &#8212; Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders, today announced upcoming presentations at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (AD\/PD\u2122 2025) being held April 1-5 in Vienna, and the American Academy of Neurology (AAN) Annual Meeting being held April 5-9 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;New Data to Be Presented at Upcoming Congresses Showcase Cerevance&#8217;s Advanced Clinical Program in Parkinson\u2019s Disease and Deep Pipeline for CNS-based Disorders&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-830497","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Data to Be Presented at Upcoming Congresses Showcase Cerevance&#039;s Advanced Clinical Program in Parkinson\u2019s Disease and Deep Pipeline for CNS-based Disorders - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Data to Be Presented at Upcoming Congresses Showcase Cerevance&#039;s Advanced Clinical Program in Parkinson\u2019s Disease and Deep Pipeline for CNS-based Disorders - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Topline results from Phase 2 ASCEND trial of solengepras as a monotherapy treatment for early-stage Parkinson\u2019s to be presented First presentation of data from Phase 1 trial of novel KCNK13 inhibitor for CNS diseases targeting neuroinflammation Additional meeting presentations highlight potential of proprietary NETSseq platform to identify novel therapeutic targets for neurodegenerative diseases \u200dBOSTON, March 27, 2025 (GLOBE NEWSWIRE) &#8212; Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders, today announced upcoming presentations at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (AD\/PD\u2122 2025) being held April 1-5 in Vienna, and the American Academy of Neurology (AAN) Annual Meeting being held April 5-9 &hellip; Continue reading &quot;New Data to Be Presented at Upcoming Congresses Showcase Cerevance&#8217;s Advanced Clinical Program in Parkinson\u2019s Disease and Deep Pipeline for CNS-based Disorders&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-27T12:09:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTI1OCM2ODMzOTA5IzIyOTg1NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"New Data to Be Presented at Upcoming Congresses Showcase Cerevance&#8217;s Advanced Clinical Program in Parkinson\u2019s Disease and Deep Pipeline for CNS-based Disorders\",\"datePublished\":\"2025-03-27T12:09:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\\\/\"},\"wordCount\":485,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMTI1OCM2ODMzOTA5IzIyOTg1NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\\\/\",\"name\":\"New Data to Be Presented at Upcoming Congresses Showcase Cerevance's Advanced Clinical Program in Parkinson\u2019s Disease and Deep Pipeline for CNS-based Disorders - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMTI1OCM2ODMzOTA5IzIyOTg1NTc=\",\"datePublished\":\"2025-03-27T12:09:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMTI1OCM2ODMzOTA5IzIyOTg1NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMTI1OCM2ODMzOTA5IzIyOTg1NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Data to Be Presented at Upcoming Congresses Showcase Cerevance&#8217;s Advanced Clinical Program in Parkinson\u2019s Disease and Deep Pipeline for CNS-based Disorders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Data to Be Presented at Upcoming Congresses Showcase Cerevance's Advanced Clinical Program in Parkinson\u2019s Disease and Deep Pipeline for CNS-based Disorders - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/","og_locale":"en_US","og_type":"article","og_title":"New Data to Be Presented at Upcoming Congresses Showcase Cerevance's Advanced Clinical Program in Parkinson\u2019s Disease and Deep Pipeline for CNS-based Disorders - Market Newsdesk","og_description":"Topline results from Phase 2 ASCEND trial of solengepras as a monotherapy treatment for early-stage Parkinson\u2019s to be presented First presentation of data from Phase 1 trial of novel KCNK13 inhibitor for CNS diseases targeting neuroinflammation Additional meeting presentations highlight potential of proprietary NETSseq platform to identify novel therapeutic targets for neurodegenerative diseases \u200dBOSTON, March 27, 2025 (GLOBE NEWSWIRE) &#8212; Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders, today announced upcoming presentations at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (AD\/PD\u2122 2025) being held April 1-5 in Vienna, and the American Academy of Neurology (AAN) Annual Meeting being held April 5-9 &hellip; Continue reading \"New Data to Be Presented at Upcoming Congresses Showcase Cerevance&#8217;s Advanced Clinical Program in Parkinson\u2019s Disease and Deep Pipeline for CNS-based Disorders\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-27T12:09:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTI1OCM2ODMzOTA5IzIyOTg1NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"New Data to Be Presented at Upcoming Congresses Showcase Cerevance&#8217;s Advanced Clinical Program in Parkinson\u2019s Disease and Deep Pipeline for CNS-based Disorders","datePublished":"2025-03-27T12:09:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/"},"wordCount":485,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTI1OCM2ODMzOTA5IzIyOTg1NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/","name":"New Data to Be Presented at Upcoming Congresses Showcase Cerevance's Advanced Clinical Program in Parkinson\u2019s Disease and Deep Pipeline for CNS-based Disorders - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTI1OCM2ODMzOTA5IzIyOTg1NTc=","datePublished":"2025-03-27T12:09:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTI1OCM2ODMzOTA5IzIyOTg1NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTI1OCM2ODMzOTA5IzIyOTg1NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"New Data to Be Presented at Upcoming Congresses Showcase Cerevance&#8217;s Advanced Clinical Program in Parkinson\u2019s Disease and Deep Pipeline for CNS-based Disorders"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/830497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=830497"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/830497\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=830497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=830497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=830497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}